Hubei Biocause Pharmaceutical (000627.SZ) subsidiary CHINA BEST Life Insurance had premium income of approximately 4.936 billion yuan in January.

Hubei Biocause Pharmaceutical (000627.SZ) issued an announcement that the company's holding subsidiary CHINA BEST Life Insurance Co., Ltd. according to...

Zhitong FinanceFeb 14 03:28 ET

Private Companies Among Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 7.4% Last Week

Simply Wall StFeb 11 00:32 ET

Tianmao Group: Tianmao Group 2024 Annual Results Forecast

SZSIJan 20 11:00 ET · Announcements

Biocause Pharmaceutical's Insurance Arm Accumulates 35 Billion Yuan in 2024 Insurance Premium Income

MT NewswiresJan 13 00:09 ET

Hubei Biocause Pharmaceutical (000627.SZ): CHINA BEST Life Insurance's cumulative original insurance premium income in 2024 is approximately 34.639 billion yuan.

Hubei Biocause Pharmaceutical (000627.SZ) issued an announcement that its holding subsidiary CHINA BEST Life Insurance Co., Ltd. 20...

Zhitong FinanceJan 10 06:26 ET

It's Down 27% But Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Could Be Riskier Than It Looks

Simply Wall StJan 6 18:30 ET